IL-23, and IL-17 were associated with a lower rate of serious infections among older adults with psoriatic disease, a ...

Risankizumab was associated with more significant improvements among patients with plaque psoriasis when compared with other biologic therapies.

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended ...

IL-23, or IL-17 reduced serious infections, while tofacitinib increased infection risk, according to one study.

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Adults taking the novel once-daily oral pill for plaque psoriasis have significantly higher rates of clear or almost clear ...

The authors recommended having awareness of potential psychiatric AEs with the use of biologics in treating psoriasis or psoriatic arthritis, guiding toward more personalized and comprehensive ...

Advancements in biologics, personalized medicine, and rising global prevalence drive the psoriasis treatment market's exponential growth.Pune, March 12, 2025 (GLOBE NEWSWIRE) -- Psoriasis Treatment ...

Tremfya is also approved to treat patients with plaque psoriasis, active psoriatic arthritis and ulcerative colitis and is ...